CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Nelarabine for Acute Lymphoblastic Leukemia - Details

Project Number PC0170-000
Brand Name Atriance
Generic Name Nelarabine
Strength 650 mg
Tumour Type Leukemia
Indication Acute Lymphoblastic Leukemia
Funding Request Individuals, aged 1–30 years, newly diagnosed with intermediate- or high-risk (CNS1 or CNS 2) T-ALL, stages II-IV, during upfront therapy.
Review Status Cancelled
Clarification Pediatric Oncology Group of Ontario has notified pCODR that they will not be filing the submission.
Pre Noc Submission No
NOC Date July 31, 2015
Manufacturer Novartis Pharmaceuticals Canada Inc.
Sponsor Pediatric Oncology Group of Ontario
Submission Date (Target Date)
Clarification The Submitter notified pCODR that they will be unable to submit by their original target date and an updated target submission date has not been provided.
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.